Demand remains low, but lab stakeholders said the industry is significantly better prepared to meet a spike in H5N1 testing ...

The digital pathology software developer is raising funding that would help it to increase its headcount and support its Aiosyn Mitosis Breast application.

NEW YORK — MRC Holland said on Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

The company said that growth in its diagnostics business was partly offset by declines in the Americas and China.

Total revenues were $3.33 billion, up from $3.03 billion in the same quarter last year and slightly above the consensus Wall Street estimate of $3.31 billion.

Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

Cubit Diagnostics announced on Tuesday that it has been awarded $2.6 million by the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) Tech program. The funding will enable the ...

The firm's Protein Sciences segment saw revenues increase 7 percent, while the Diagnostics and Spatial Biology segment's revenues rose 12 percent.

Qiagen said the intellectual property in question covers technologies used in its QuantiFeron latent tuberculosis assays.